PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 186 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2014. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $82,195,000 | +21.0% | 2,209,599 | -0.1% | 0.07% | +17.5% |
| Q4 2016 | $67,922,000 | -55.7% | 2,212,313 | -3.3% | 0.06% | -55.8% |
| Q3 2016 | $153,395,000 | +102.7% | 2,287,774 | -9.9% | 0.13% | +101.6% |
| Q2 2016 | $75,675,000 | +32.4% | 2,540,331 | +30.6% | 0.06% | +28.0% |
| Q1 2016 | $57,141,000 | +24.1% | 1,945,510 | +231.3% | 0.05% | +28.2% |
| Q4 2015 | $46,044,000 | -45.7% | 587,302 | -47.8% | 0.04% | +2.6% |
| Q3 2015 | $84,804,000 | -8.0% | 1,125,330 | +42.5% | 0.04% | -50.0% |
| Q2 2015 | $92,212,000 | -28.9% | 789,824 | +43.8% | 0.08% | -29.0% |
| Q1 2015 | $129,660,000 | +78.1% | 549,150 | +42.8% | 0.11% | +72.6% |
| Q4 2014 | $72,793,000 | +2.6% | 384,598 | +29.3% | 0.06% | -4.6% |
| Q3 2014 | $70,957,000 | +113.5% | 297,425 | -40.9% | 0.06% | +116.7% |
| Q2 2014 | $33,238,000 | +5.9% | 503,608 | +67.2% | 0.03% | +3.4% |
| Q1 2014 | $31,372,000 | +26.5% | 301,246 | +25.8% | 0.03% | +26.1% |
| Q4 2013 | $24,793,000 | – | 239,472 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Copernicus Capital Management, LLC | 65,742 | $6,499,000 | 4.84% |
| PFM Health Sciences, LP | 1,821,800 | $180,085,000 | 4.27% |
| Redmile Group, LLC | 913,573 | $90,307,000 | 3.93% |
| BERYLSON CAPITAL PARTNERS, LLC | 24,800 | $2,451,000 | 3.77% |
| Eversept Partners, LP | 54,649 | $5,402,054 | 3.11% |
| Partner Investment Management, L.P. | 26,369 | $2,607,000 | 3.00% |
| Crosspoint Capital Strategies, LLC | 35,349 | $34,942,000 | 2.89% |
| Orbimed Advisors | 2,184,535 | $215,941,000 | 2.73% |
| Perceptive Advisors | 703,820 | $69,573,000 | 2.31% |
| Rock Springs Capital Management LP | 373,500 | $36,920,000 | 1.68% |